IN2014MN01376A - - Google Patents
Info
- Publication number
- IN2014MN01376A IN2014MN01376A IN1376MUN2014A IN2014MN01376A IN 2014MN01376 A IN2014MN01376 A IN 2014MN01376A IN 1376MUN2014 A IN1376MUN2014 A IN 1376MUN2014A IN 2014MN01376 A IN2014MN01376 A IN 2014MN01376A
- Authority
- IN
- India
- Prior art keywords
- ihmvyskrsgkprgyafiey
- peptide
- salt
- amino acid
- acid sequence
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000004481 post-translational protein modification Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2011/003256 WO2013088194A1 (en) | 2011-12-13 | 2011-12-13 | Modified peptides and their use for treating autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01376A true IN2014MN01376A (OSRAM) | 2015-04-17 |
Family
ID=45607295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1376MUN2014 IN2014MN01376A (OSRAM) | 2011-12-13 | 2011-12-13 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9657072B2 (OSRAM) |
| EP (2) | EP3202413B1 (OSRAM) |
| JP (1) | JP6060175B2 (OSRAM) |
| KR (2) | KR20170020556A (OSRAM) |
| CN (2) | CN106986927A (OSRAM) |
| AU (2) | AU2011383222C1 (OSRAM) |
| BR (1) | BR112014014492B1 (OSRAM) |
| CA (1) | CA2858957C (OSRAM) |
| DK (2) | DK3202413T3 (OSRAM) |
| ES (1) | ES2618402T3 (OSRAM) |
| HU (1) | HUE032552T2 (OSRAM) |
| IN (1) | IN2014MN01376A (OSRAM) |
| RU (1) | RU2620070C2 (OSRAM) |
| WO (1) | WO2013088194A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213482B2 (en) * | 2014-12-12 | 2019-02-26 | Immupharma France Sa | Methods of treating chronic inflammatory diseases |
| CN109312379B (zh) | 2016-04-05 | 2022-04-12 | 科学与工业研究委员会 | 多功能重组核苷酸依赖性糖基转移酶蛋白及其糖基化的方法 |
| WO2018109285A1 (fr) * | 2016-12-13 | 2018-06-21 | Centre National De La Recherche Scientifique | Peptides pour le traitement du neurolupus |
| WO2021198135A1 (en) * | 2020-03-29 | 2021-10-07 | Immupharma France Sa | Method of treating viral infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| CA2459811C (en) * | 2001-09-06 | 2012-03-13 | Cnrs-Centre National De La Recherche Scientifique | Modified peptides and their use for the treatment of autoimmune diseases |
| FR2829768B1 (fr) * | 2001-09-18 | 2003-12-12 | Centre Nat Rech Scient | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes |
| EP2450368A1 (en) * | 2007-01-30 | 2012-05-09 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| FR2931360B1 (fr) * | 2008-05-20 | 2012-05-18 | Centre Nat Rech Scient | Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs |
-
2011
- 2011-12-13 JP JP2014546657A patent/JP6060175B2/ja active Active
- 2011-12-13 HU HUE11817532A patent/HUE032552T2/en unknown
- 2011-12-13 ES ES11817532.2T patent/ES2618402T3/es active Active
- 2011-12-13 CN CN201611107686.XA patent/CN106986927A/zh active Pending
- 2011-12-13 AU AU2011383222A patent/AU2011383222C1/en active Active
- 2011-12-13 DK DK16195776.6T patent/DK3202413T3/en active
- 2011-12-13 CA CA2858957A patent/CA2858957C/en active Active
- 2011-12-13 EP EP16195776.6A patent/EP3202413B1/en active Active
- 2011-12-13 KR KR1020177004246A patent/KR20170020556A/ko not_active Ceased
- 2011-12-13 EP EP11817532.2A patent/EP2790715B1/en active Active
- 2011-12-13 BR BR112014014492-3A patent/BR112014014492B1/pt active IP Right Grant
- 2011-12-13 RU RU2014128612A patent/RU2620070C2/ru active
- 2011-12-13 DK DK11817532.2T patent/DK2790715T3/en active
- 2011-12-13 IN IN1376MUN2014 patent/IN2014MN01376A/en unknown
- 2011-12-13 KR KR1020147019394A patent/KR101728784B1/ko active Active
- 2011-12-13 CN CN201180076376.5A patent/CN104114180B/zh active Active
- 2011-12-13 WO PCT/IB2011/003256 patent/WO2013088194A1/en active Application Filing
-
2014
- 2014-12-05 US US14/562,350 patent/US9657072B2/en active Active
-
2017
- 2017-01-12 AU AU2017200207A patent/AU2017200207B2/en active Active
- 2017-04-18 US US15/490,378 patent/US20170226167A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015501831A (ja) | 2015-01-19 |
| CN104114180B (zh) | 2017-01-18 |
| EP2790715B1 (en) | 2016-12-07 |
| US20170226167A1 (en) | 2017-08-10 |
| CA2858957C (en) | 2019-09-03 |
| DK2790715T3 (en) | 2017-03-20 |
| BR112014014492B1 (pt) | 2022-05-24 |
| WO2013088194A1 (en) | 2013-06-20 |
| EP2790715A1 (en) | 2014-10-22 |
| AU2017200207A1 (en) | 2017-02-02 |
| KR101728784B1 (ko) | 2017-04-21 |
| ES2618402T3 (es) | 2017-06-21 |
| CN106986927A (zh) | 2017-07-28 |
| RU2620070C2 (ru) | 2017-05-22 |
| JP6060175B2 (ja) | 2017-01-11 |
| AU2017200207B2 (en) | 2018-03-01 |
| US20150111835A1 (en) | 2015-04-23 |
| AU2011383222C1 (en) | 2017-04-20 |
| KR20170020556A (ko) | 2017-02-22 |
| AU2011383222A1 (en) | 2014-07-03 |
| EP3202413B1 (en) | 2018-08-01 |
| CA2858957A1 (en) | 2013-06-20 |
| HUE032552T2 (en) | 2017-09-28 |
| KR20140114365A (ko) | 2014-09-26 |
| AU2011383222B2 (en) | 2016-10-27 |
| BR112014014492A2 (pt) | 2020-10-27 |
| DK3202413T3 (en) | 2018-11-19 |
| RU2014128612A (ru) | 2016-02-10 |
| US9657072B2 (en) | 2017-05-23 |
| CN104114180A (zh) | 2014-10-22 |
| EP3202413A1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274204B (en) | Preparations Containing, Methods Involving, and Uses of Unnatural Amino Acids Related to Dolastatin History | |
| IL239425A0 (en) | Zinc Amino Acid Halide Mouthwashes | |
| IL229353A0 (en) | Preparations containing, methods involving and uses of unnatural amino acids related to the history of dolastatin | |
| EP2771033A4 (en) | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS | |
| ZA201503846B (en) | Zinc amino acid/trimethylglycine halide | |
| GB201315335D0 (en) | Amino diacids containing peptide modifiers | |
| MY167847A (en) | Intra-mode video coding | |
| EP2760471A4 (en) | THERAPEUTIC PEPTIDES | |
| IL231824A0 (en) | Formulations of etanercept stabilized with amino acids | |
| CO6900146A2 (es) | Imidazopiridazinas sustituidas con amino | |
| AU2011356210A8 (en) | Novel fucosyltransferases and their applications | |
| DK2797616T3 (da) | Celle-penetrerende peptider | |
| UA118167C2 (uk) | Пептид та його застосування | |
| TWI561242B (en) | Long-acting peptide analogs | |
| IL238777A0 (en) | Skin care preparations containing an unnatural hygroscopic amino acid | |
| WO2013000922A9 (en) | Ccr2 antagonist peptides | |
| GB201111183D0 (en) | Peptide | |
| IN2014DN09367A (OSRAM) | ||
| EP2813488A4 (en) | BASIC AMINO ACID DERIVATIVES WITH AMPHOTEEN IONES | |
| SG10201606218WA (en) | Purified Proteins | |
| MX351610B (es) | Sales acidas de adicion de 5alfa-hidroxi-6beta-[2-(1h-imidazol-4-i l)etilamino]colestan-3beta-ol. | |
| IN2014MN01376A (OSRAM) | ||
| EP2646458A4 (en) | Deuterated peptides | |
| MX362393B (es) | Cassette de expresion. | |
| EP3067430A4 (en) | Method for producing d-form or l-form amino acid derivative having thiol group |